Published in Mov Disord on March 01, 1995
Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry (1998) 1.52
Genetic and clinical features of primary torsion dystonia. Neurobiol Dis (2010) 1.00
Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. J Neurol Neurosurg Psychiatry (1999) 0.94
Sensory representation abnormalities that parallel focal hand dystonia in a primate model. Somatosens Mot Res (2002) 0.91
Spread of primary dystonia in relation to initially affected region. J Neurol (2007) 0.90
The dystonias. J Med Genet (1998) 0.88
Early onset torsion dystonia (Oppenheim's dystonia). Orphanet J Rare Dis (2006) 0.81
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatr Dis Treat (2011) 0.80
Animal models of focal dystonia. NeuroRx (2005) 0.80
Familial adolescent-onset scoliosis and later segmental dystonia in an Irish family. J Neurol (2004) 0.79
Research Priorities in Limb and Task-Specific Dystonias. Front Neurol (2017) 0.78
Diminishing evidence for torsinA-positive neuronal inclusions in DYT1 dystonia. Acta Neuropathol Commun (2016) 0.75
Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord (2016) 0.75
Deep brain stimulation in childhood: an effective treatment for early onset idiopathic generalised dystonia. Arch Dis Child (2007) 0.75
Idiopathic adult onset action dystonia of the lower limbs: case reports. J Neurol (2011) 0.75
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 6.03
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry (1980) 3.19
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. Neuroepidemiology (1997) 2.96
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol (1996) 2.86
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
The DYT1 phenotype and guidelines for diagnostic testing. Neurology (2000) 2.39
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
Idiopathic cervical dystonia: clinical characteristics. Mov Disord (1991) 2.21
Accuracy of family history data on Parkinson's disease. Neurology (2003) 2.15
Functional brain networks in DYT1 dystonia. Ann Neurol (1998) 2.14
Oral and genital tardive pain syndromes. Neurology (1994) 2.07
What is it? Case 3, 1991: moaning in a man with parkinsonian signs. Mov Disord (1991) 2.05
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Distant effects of local injection of botulinum toxin. Muscle Nerve (1987) 2.02
Motor blocks in Parkinson's disease. Neurology (1992) 2.01
Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol (1989) 2.00
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology (1994) 1.97
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord (1987) 1.92
Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology (2007) 1.90
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord (1994) 1.88
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. I. An associated sodium-activated transphosphorylation. J Biol Chem (1966) 1.86
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci (1992) 1.79
Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet (1993) 1.78
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology (1990) 1.77
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol (1988) 1.72
Selegiline and mortality in Parkinson's disease. Ann Neurol (1996) 1.67
Delayed-onset cerebellar syndrome. Arch Neurol (1996) 1.65
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. II. Effects of N-ethylmaleimide and other sulfhydryl reagents. J Biol Chem (1966) 1.62
Chronic manganese intoxication. Arch Neurol (1974) 1.61
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab (1993) 1.52
High dosage anticholinergic therapy in dystonia. Neurology (1983) 1.52
Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry (1998) 1.52
Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol (1995) 1.51
Laserlight cues for gait freezing in Parkinson's disease: an open-label study. Parkinsonism Relat Disord (2010) 1.51
Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience (1999) 1.50
Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 1.50
Unilateral globus pallidus internus stimulation improves delayed onset post-traumatic cervical dystonia with an ipsilateral focal basal ganglia lesion. J Neurol Neurosurg Psychiatry (2002) 1.47
Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology (1991) 1.46
Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology (1981) 1.46
The clinical spectrum of posthypoxic myoclonus. Mov Disord (2000) 1.46
Movement disorder in reflex sympathetic dystrophy: a case proven to be psychogenic by surveillance video monitoring. Mov Disord (1997) 1.45
Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord (1989) 1.44
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology (1974) 1.44
Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology (1979) 1.43
Welcome news about levodopa, but uncertainty remains. Ann Neurol (1998) 1.42
Regional distribution of gamma-aminobutyric acid (GABA) in brain of the rhesus monkey. J Neurochem (1968) 1.41
Tourette syndrome. Arch Neurol (1996) 1.39
Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology (1991) 1.39
Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology (1986) 1.38
Definition of dystonia and classification of the dystonic states. Adv Neurol (1976) 1.36
Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol (1997) 1.34
Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope (1986) 1.33
An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol (1988) 1.33
Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology (2002) 1.32
Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet (1990) 1.31
Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med (1980) 1.28
Primary sensory symptoms in parkinsonism. Neurology (1976) 1.26
A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol (2000) 1.22
Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Ann Neurol (1994) 1.19
Normal pressure hydrocephalus and hypertensive cerebrovascular disease. Arch Neurol (1974) 1.19
The varied clinical expressions of dystonia. Neurol Clin (1984) 1.17
Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol (1979) 1.16
Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology (1995) 1.16
Normal pressure hydrocephalus and Parkinson's disease. J Neural Transm Suppl (1983) 1.16
The natural history of embouchure dystonia. Mov Disord (2001) 1.15
Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Mov Disord (1996) 1.14
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope (1988) 1.14
Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol (1989) 1.14
Fatigue in levodopa-naive subjects with Parkinson disease. Neurology (2008) 1.13
Treatment of vascular hemiballism and hemichorea. Neurology (1977) 1.13
Diagnostic criteria for dystonia in DYT1 families. Neurology (2002) 1.12
The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry (2002) 1.11
Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. Neurology (2003) 1.09
The effect of estrogen replacement on early Parkinson's disease. Neurology (1999) 1.07
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol (1995) 1.06
The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry (1991) 1.05
The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics (1999) 1.05
Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. Neurology (2000) 1.05
Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up. J Neurol Neurosurg Psychiatry (2004) 1.05
Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci (1971) 1.04
The phenomenology of tics. Mov Disord (1986) 1.04
The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord (1990) 1.03